#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

May 25, 2026 Episode Page ↗
Overview

In AMA #85, Peter Attia, MD, explores critical thinking about medications and supplements, emphasizing defining health problems with actionable metrics, classifying interventions by purpose, and evaluating evidence and risks. He highlights why skepticism is crucial, especially for 'optimization' claims, to make informed personal health decisions.

At a Glance
8 Insights
13m 6s Duration
10 Topics
4 Concepts

Deep Dive Analysis

Introduction to AMA 85: Medications and Supplements

Defining Health Problems for Effective Intervention

Importance of Actionable Metrics, Thresholds, and Timelines

The Counterfactual: Consequences of Doing Nothing

Classifying Intervention Purpose and Evidence Standards

Evidence Thresholds for Disease Treatment

Evidence Thresholds for Symptom Relief

Evidence Thresholds for Risk Reduction

Evidence Thresholds for Optimization and Longevity Interventions

Avoiding Confusion in Evidence Tiers

Actionable Problem Definition

This is a framework for defining a health problem with specific, measurable metrics, a target threshold, and a timeline, rather than vague goals. It ensures interventions can be objectively evaluated and prevents self-deception.

Counterfactual

The hypothetical outcome of a situation if no intervention is taken. Considering the counterfactual helps assess whether a problem truly warrants intervention by understanding its natural progression or potential downstream consequences.

Intervention Job Classification

A framework categorizing medications or supplements into four purposes: disease treatment, symptom relief, risk reduction, or optimization. This classification is critical for determining the appropriate evidence standard and acceptable risk for any given intervention.

Validated Surrogate Biomarker

A measurable indicator that is not the direct clinical endpoint but is strongly and reliably correlated with it. It allows for the evaluation of intervention effectiveness when hard outcomes are difficult to measure, such as ApoB for cardiovascular risk.

?
How should one define a health problem before considering medication or supplements?

One should define problems with actionable metrics, specific thresholds, and a timeline, also considering the counterfactual (what happens if nothing is done) to avoid vague goals and self-deception.

?
How does the 'job' of a medication or supplement influence required evidence and risk tolerance?

The 'job' (disease treatment, symptom relief, risk reduction, or optimization) dictates the evidence bar and acceptable risk; more serious problems warrant higher evidence and potentially more risk, while speculative goals require less tolerance for downside.

?
Why does Peter Attia suggest supplements deserve more skepticism?

Supplements often fall into the 'optimization' category, where error rates are highest, expected effects are small, claims are mechanistic, and objective measurement is difficult, making self-deception common.

1. Define Problems Actionably

Instead of vague goals like ‘be healthier,’ define problems with specific, measurable metrics, a target threshold, and a timeline. This approach helps prevent self-deception and ensures interventions can be objectively evaluated.

2. Consider the Counterfactual

Before starting any intervention, ask what would happen if you did nothing. This helps separate real problems that meaningfully increase risk or reduce quality of life from those that merely feel actionable.

3. Classify Intervention’s ‘Job’

Categorize the purpose of a medication or supplement into one of four buckets: disease treatment, symptom relief, risk reduction, or optimization. This classification is crucial for determining the appropriate evidence threshold and acceptable risk.

4. Demand Strong Evidence for Disease Treatment

For interventions aimed at treating a disease, require strong evidence such as hard outcome trials or well-validated surrogate endpoints. You may be willing to accept more downside risk due to the seriousness of the underlying problem.

5. Prioritize Lived Benefit for Symptom Relief

When the goal is symptom relief, focus on whether the person actually feels or functions better. While acknowledging placebo risk and safety unknowns, a low-downside intervention that improves subjective symptoms can be a reasonable trade-off.

6. Require High Evidence for Risk Reduction

For interventions focused on risk reduction, which often treat conditions a person cannot feel, demand high-quality evidence like hard outcomes or very well-validated surrogate markers (e.g., ApoB), rather than vague inflammatory markers.

7. Approach Optimization with Skepticism

For ‘optimization’ interventions, especially when starting from a healthy baseline, maintain a high degree of skepticism. Claims are often mechanistic, expected effects are small, and objective measurement is difficult, making self-deception common.

8. Be Skeptical of Longevity Interventions

Many so-called ’longevity interventions’ are actually optimizations masquerading as risk reductions. They often borrow the language of prevention but lack strong evidence, requiring increased skepticism regarding both efficacy and safety.

The right question is whether a specific intervention makes sense for a specific person with a specific problem.

Peter Attia

Do not start with the molecule. Start with the problem. Define tightly enough that you could actually be proven wrong.

Peter Attia

If the problem is vague, almost anything can look like it helped.

Peter Attia

Most of the longevity interventions are really really optimizations masquerading as risk reductions.

Peter Attia
130 milligrams per deciliter
ApoB level Initial level, with a goal to get it below 60 milligrams per deciliter within six months.
60 minutes
Time to fall asleep (sleep latency) Initial time on four or five nights a week, with a goal to reduce it to under 10 minutes within two months.